PP15 The National Pricing And Reimbursement Process In China, A 2021 Update

Introduction The Chinese National Reimbursement Drug List (NRDL) was established in the early 2000’s and includes drugs both fully partially covered by Basic Medicine Insurance. As China’s health system has been reformed over past decade, it is important for manufacturers to understand ever-changing reimbursement process its implications on newly launched drugs. This study provides an updated overview of based research conducted 2021. Methods Targeted secondary undertaken evaluate pricing landscape China. Primary assess perspectives three payers one policy expert. Results listing remains most viable exclusive pathway get a product reimbursed public insurance Since 2017, NRDL annually, revisions are managed Healthcare Security Administration (NHSA). Insights from 2021 suggests that new lasts five months (July November). Manufacturers should ensure submissions made when annual formally begins, clinical economic evidence compulsory. If successful opinion assessment board, manufacturer will be invited negotiate price with NHSA. Data NHSA indicated total 704 applications were 2020. In addition, 138 eligible negotiation, which 96 added NRDL. Findings also suggested average discount rate increased 44.0 percent 2017 50.6 Conclusions national China become more transparent overtime. Even so, challenge, decisions driven pharmacoeconomic evidence, price. Significant cuts considered anticipated negotiation outcomes.